Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.63 |
| ▸ | CA2 | P00918 | 7/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.63 |
| ▸ | CA1 | P00915 | 8/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762491 | 0.90 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762313 | 0.88 | TDP1 (0.58) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762328 | 0.87 | TDP1 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL20646495 | 0.86 | CA12 (0.63) | CA12CA2CA14CA1CA7 | |
| SCHEMBL18756420 | 0.84 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL19925453 | 0.84 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL17233254 | 0.84 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL19004206 | 0.84 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22404228 | 0.83 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL14010825 | 0.83 | CA12 (0.64) | CA12CA2CA14CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600299-B1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | NIKANG THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11034661-B2 | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3820474-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | Nikang Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200102278-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE IDO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-04-02 | — | — | US | disclosed |
| EP-3600299-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110461326-A | Novel substituted N' -hydroxycarbamimidoyl-1, 2, 5-oxadiazole compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME | 2019-11-15 | — | — | CN | disclosed |
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
| WO-2018183097-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-8293256-B2 | Sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2012-10-23 | — | — | US | disclosed |
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2011-02-24 | — | — | US | disclosed |
| US-7887824-B2 | such as N,N'-bis(2-hydroxyethyl)sulfamide; improved elasticity on stratum corneum | L'OREAL (FR) | 2011-02-15 | — | — | US | disclosed |
| US-20060134151-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | ADORA2A, ADORA1, ADORA3 | CA12 3897/4885CA2 2428/4885CA14 3828/4885 |
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | STS, TST, TPST2 | CA12 2571/4885CA2 1701/4885CA14 2598/4885 |
| US-20060134151-A1 | Novel sulfamide derivatives and cosmetic use thereof | STS, TST, TPST2 | CA12 2571/4885CA2 1701/4885CA14 2598/4885 |
| US-20200102278-A1 | NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE IDO INHIBITORS | IDO1, IDO2, INMT | CA12 1685/4885CA2 1420/4885CA14 1734/4885 |
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | IDO1, IDO2, INMT | CA12 3220/4885CA2 2628/4885CA14 3685/4885 |
| US-11034661-B2 | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors | IDO1, IDO2, INMT | CA12 1615/4885CA2 1629/4885CA14 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.